Evidence map›Paper›PMID 35286704›Full record

ArticleAdvances in experimental medicine and biology2022

The Immunogenetics of Melanoma.

Farzaneh Darbeheshti

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Farzaneh DarbeheshtiDepartments of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. bdarbeheshti70@gmail.com.ORCID http://orcid.org/0000-0002-4957-9004
Universal Scientific Education and Research Network · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is a relatively common and deadly type of skin cancer that originates from melanocytes. Cutaneous malignant melanoma results from the interplay between genetic susceptibility and environmental factors. Though the majority of melanoma cases are sporadic, several high and low penetrance mutations have been identified as underlying factors of heritable melanoma. Genetic variations in immune system components are among the most studied factors in melanoma heritability. They are involved in several aspects of the pathogenesis of the tumor including predisposition, cell proliferation, and apoptosis as well as immunotherapy. In this chapter, the hitherto available immunogenetic-related reports on melanoma predisposition and progression are summed up.

Indexed as

MelanomaSkin NeoplasmsGenetic Predisposition to DiseaseHumansImmunogeneticsMelanocytesGenetic susceptibilityImmunogeneticsMelanomaPathogenesis

Identifiers

PMID35286704
OpenAlexW4225349704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.